These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24246863)

  • 1. [Expression of glucose transporter protein 1 and desmin in reactive mesothelial hyperplasia and epithelioid malignant mesothelioma].
    Wei P; Jin ML; Zhao HY; Li X; Diao XL
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):451-4. PubMed ID: 24246863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.
    Mogi A; Koga K; Aoki M; Hamasaki M; Uesugi N; Iwasaki A; Shirakusa T; Tamura K; Nabeshima K
    Virchows Arch; 2013 Jan; 462(1):83-93. PubMed ID: 23187830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
    Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
    Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
    Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
    Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
    Kushitani K; Amatya VJ; Mawas AS; Miyata Y; Okada M; Takeshima Y
    Pathobiology; 2016; 83(1):33-40. PubMed ID: 26735863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
    Lagana SM; Taub RN; Borczuk AC
    Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma and non-neoplastic mesothelial cells.
    Tsukiji H; Takeshima Y; Amatya VJ; Kushitani K; Inai K
    Histopathology; 2010 Jun; 56(7):969-74. PubMed ID: 20636799
    [No Abstract]   [Full Text] [Related]  

  • 11. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. My approach to the diagnosis of mesothelial lesions.
    Butnor KJ
    J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].
    Liu Y; Chen X; Ding N; Xu W; Yang H; Chen X
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):262-5. PubMed ID: 25975910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
    Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
    Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
    Hakim SA; Abou Gabal HH
    Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
    Attanoos RL; Griffin A; Gibbs AR
    Histopathology; 2003 Sep; 43(3):231-8. PubMed ID: 12940775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
    Monaco SE; Shuai Y; Bansal M; Krasinskas AM; Dacic S
    Am J Clin Pathol; 2011 Apr; 135(4):619-27. PubMed ID: 21411785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-catenin expression in benign and malignant pleural disorders.
    Anani W; Bruggeman R; Zander DS
    Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant mesothelioma of the pleura. Morphometric study].
    Serio G; Caniglia DM; Pennella A; Giardina C; Dalena AM; Serio R; Lettini T; Ricco R
    Pathologica; 1997 Apr; 89(2):122-7. PubMed ID: 9411357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.